Geode Capital Management LLC raised its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 21.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 366,148 shares of the medical instruments supplier’s stock after buying an additional 64,707 shares during the period. Geode Capital Management LLC’s holdings in AngioDynamics were worth $6,352,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp increased its position in AngioDynamics by 21.4% in the fourth quarter. State Street Corp now owns 801,613 shares of the medical instruments supplier’s stock valued at $13,518,000 after buying an additional 141,424 shares during the last quarter. Norges Bank acquired a new position in AngioDynamics during the fourth quarter valued at $2,699,000. Teachers Advisors LLC increased its position in AngioDynamics by 33.2% in the fourth quarter. Teachers Advisors LLC now owns 83,187 shares of the medical instruments supplier’s stock valued at $1,403,000 after buying an additional 20,754 shares during the last quarter. Fenimore Asset Management Inc. acquired a new position in AngioDynamics during the first quarter valued at $9,214,000. Finally, Louisiana State Employees Retirement System increased its position in AngioDynamics by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 13,000 shares of the medical instruments supplier’s stock valued at $226,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 85.84% of the company’s stock.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) traded up 0.12% during mid-day trading on Tuesday, hitting $16.58. 8,101 shares of the stock were exchanged. AngioDynamics, Inc. has a 52-week low of $14.80 and a 52-week high of $18.18. The company has a market cap of $607.72 million, a P/E ratio of 87.26 and a beta of 1.15. The stock’s 50-day moving average price is $16.13 and its 200-day moving average price is $16.18.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million during the quarter, compared to analysts’ expectations of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. Equities research analysts anticipate that AngioDynamics, Inc. will post $0.67 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Geode Capital Management LLC Acquires 64,707 Shares of AngioDynamics, Inc. (ANGO)” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/08/geode-capital-management-llc-acquires-64707-shares-of-angiodynamics-inc-ango.html.
Several research analysts have weighed in on ANGO shares. Zacks Investment Research downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. Canaccord Genuity reiterated a “hold” rating and issued a $16.50 price target on shares of AngioDynamics in a research report on Wednesday, May 31st. Cantor Fitzgerald increased their price target on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Barclays PLC decreased their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 19th. Finally, BidaskClub downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. AngioDynamics presently has a consensus rating of “Hold” and a consensus target price of $18.50.
In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was acquired at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James C. Clemmer bought 5,000 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were acquired at an average cost of $15.79 per share, with a total value of $78,950.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The disclosure for this purchase can be found here. Insiders have bought 25,316 shares of company stock valued at $396,806 in the last ninety days. Insiders own 1.88% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
